Use of sdha as a prognostic marker and therapeutic target in uveal melanoma
AssigneeBoard of Regents, The University of Texas System
InventorsChandrani CHATTOPADHYAY, Janos ROSZIK
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
Claims84
An in vitro method for detecting the expression of succinate dehydrogenase complex flavoprotein subunit A (SDHA) in a sample comprising:
- (a) obtaining a sample from a subject diagnosed with or at risk for uveal melanoma;
- (b) isolating RNA from the sample;
- and
- (c) detecting an elevated expression of SDHA RNA.
An in vitro method for detecting expression of SDHA and MIF in a sample comprising:
- (a) obtaining a sample;
- (b) isolating RNA from the sample;
- and
- (c) detecting gene expression of SDHA and MIF in the RNA.
A method of treating cancer in a subject comprising:
- (a) determining an expression level of SDHA in a patient sample;
- and
- (b) administering an effective amount of an SDHA inhibitor and an OXPHOS inhibitor to the patient identified to have an elevated expression of SDHA.
A composition comprising an effective amount of an SDHA inhibitor and an OXPHOS inhibitor for the treatment of cancer in a subject, wherein the subject is identified to have an elevated expression of SDHA.
A method for treating a cancer in a subject comprising administering an effective amount of an SDHA inhibitor to the subject.
Dependencies are inferred from the claim text.